Part B: Supplementary Information Sheet (SIS) |
FR Recognition List Number
|
021
|
Date of Entry 03/18/2009
|
FR Recognition Number
|
7-176
|
Standard | |
CLSI I/LA30-A (Replaces I/LA30-P) Immunoassay Interference by Endogenous Antibodies; Approved Guideline. |
|
Scope/AbstractThis standard presents information on the origin, nature, and prevalence of circulating endogenous antibodies, which cause interference with immunoassay results. The mechanisms of the interference along with some specific examples are included. To address the problem, recommendations for regulatory bodies, reagent manufacturers, and laboratorians are provided. |
|
Extent of Recognition
|
Public Law, CFR Citation(s) and Procode(s)*
All assays that utilize immunoassay methods/reagents |
|
Relevant FDA Guidance and/or Supportive Publications*
Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices - Guidance for Industry and Food and Drug Administration Staff, issued September 2018. |
|
FDA Technical Contact
|
Standards Development Organization
|
FDA Specialty Task Group (STG)
|
*These are provided as examples and others may be applicable. |